ASML vs. Broadcom: Which AI Stock Is a Better Buy?

ASML reported 2025 net sales of €32.7B (+~15% YoY), net income €9.6B, year-end backlog €38.8B and guided 2026 sales €34–39B (midpoint +11.6%); the stock trades at ~40x forward P/E. Broadcom posted fiscal Q1 2026 revenue of $19.3B (+29% YoY) with AI semiconductor revenue of $8.4B (+106% YoY) and management sees line-of-sight to >$100B AI chip revenue in 2027; the stock trades at ~29x forward P/E. The article concludes Broadcom offers a better risk-reward than ASML given its explosive AI growth and lower valuation, while noting Broadcom's hyperscaler concentration is a residual risk.

Analysis

ASML’s uniqueness in EUV is less a steady annuity than a lumpy, duration-sensitive revenue stream. One delayed fab decision or a multi-quarter desynchronization between foundry capex and machine deliveries produces a concentrated revenue shortfall because product cadence is measured in quarters-to-years and cancellations or push-outs can’t be filled by low-margin aftermarket sales. That makes valuation highly path-dependent: downside risk is asymmetric because a high multiple compounds the impact of any single timing miss.

Broadcom’s commercial edge is structural lock-in — custom silicon + firmware/software bundles create switching costs for hyperscalers and telecom customers, turning episodic chip wins into multi-year revenue streams. That concentration concentrates both upside (fast, visible ramps when hyperscalers stick to plans) and downside (a single strategic pivot by a top customer materially lowers growth expectations). The net effect: Broadcom’s cash-flow optionality is higher-frequency and more hedgeable than ASML’s long-lead, high-ticket equipment exposures.

Practically, this dichotomy creates a clean relative-value trade: sell asymmetric, low-frequency risk (ASML exposure to timing/geopolitics) and buy higher-frequency cash-flow optionality (Broadcom-style exposure) while hedging customer-concentration risk. Execution should favor structures that monetize the valuation stretch rather than blunt directional bets — e.g., time-limited option spreads and dollar/sector-neutral pairs sized to limit single-name idiosyncratic gamma over the next 6–18 months.

Key Decisions for Investors

• Initiate a 12-month pair trade: short ASML and long AVGO in equal dollar amounts to be beta-neutral to the semis index. Size such that max portfolio exposure to either leg is ~2% NAV. Target return 25–40% if multiple reversion + relative outperformance occurs; stop-loss: 12% adverse move on either leg and reassess on catalysts (fab confirmations or major hyperscaler commentary).
• Buy a 9–12 month AVGO call spread (long call / sell higher strike call) to capture continued AI-driven take-rate while limiting premium paid. Fund by buying ASML 9–12 month puts (or selling ASML covered calls against a short position) to create a skewed payoff: positive if Broadcom rerates or ASML hits a timing miss. Risk: defined premium; reward: asymmetric if AVGO re-rating coincides with ASML multiple compression.
• For downside protection against AVGO hyperscaler concentration risk, buy a 6–9 month out-of-the-money put on AVGO sized to cover 25–30% of the long exposure. This keeps upside participation while capping tail loss if hyperscalers materially slow AI capex.
• If you prefer pure tail hedge: purchase deep 18–24 month ASML put LEAPs at a low delta to protect the portfolio from a binary geopolitical/export-control event that would materially shrink ASML’s addressable market. Cost is small relative to portfolio insurance value; payout is large in the event of an adverse regulatory shock.